|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FLNB |
Gene summary for FLNB |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FLNB | Gene ID | 2317 |
| Gene name | filamin B | |
| Gene Alias | ABP-278 | |
| Cytomap | 3p14.3 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | O75369 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2317 | FLNB | LZE22T | Human | Esophagus | ESCC | 1.97e-02 | 2.66e-01 | 0.068 |
| 2317 | FLNB | LZE24T | Human | Esophagus | ESCC | 3.21e-16 | 2.52e-01 | 0.0596 |
| 2317 | FLNB | LZE21T | Human | Esophagus | ESCC | 3.47e-07 | 4.26e-01 | 0.0655 |
| 2317 | FLNB | P1T-E | Human | Esophagus | ESCC | 4.20e-03 | 1.99e-01 | 0.0875 |
| 2317 | FLNB | P2T-E | Human | Esophagus | ESCC | 6.03e-24 | 4.11e-01 | 0.1177 |
| 2317 | FLNB | P4T-E | Human | Esophagus | ESCC | 1.22e-15 | 3.95e-01 | 0.1323 |
| 2317 | FLNB | P5T-E | Human | Esophagus | ESCC | 1.97e-33 | 8.47e-01 | 0.1327 |
| 2317 | FLNB | P8T-E | Human | Esophagus | ESCC | 4.09e-23 | 3.88e-01 | 0.0889 |
| 2317 | FLNB | P9T-E | Human | Esophagus | ESCC | 4.25e-06 | 1.13e-01 | 0.1131 |
| 2317 | FLNB | P10T-E | Human | Esophagus | ESCC | 2.34e-26 | 2.47e-01 | 0.116 |
| 2317 | FLNB | P11T-E | Human | Esophagus | ESCC | 1.35e-05 | 5.39e-01 | 0.1426 |
| 2317 | FLNB | P12T-E | Human | Esophagus | ESCC | 1.78e-31 | 6.38e-01 | 0.1122 |
| 2317 | FLNB | P15T-E | Human | Esophagus | ESCC | 3.00e-18 | 4.37e-01 | 0.1149 |
| 2317 | FLNB | P16T-E | Human | Esophagus | ESCC | 1.92e-09 | 1.49e-01 | 0.1153 |
| 2317 | FLNB | P17T-E | Human | Esophagus | ESCC | 4.01e-05 | 2.60e-01 | 0.1278 |
| 2317 | FLNB | P20T-E | Human | Esophagus | ESCC | 2.19e-15 | 2.79e-01 | 0.1124 |
| 2317 | FLNB | P21T-E | Human | Esophagus | ESCC | 6.87e-30 | 7.58e-01 | 0.1617 |
| 2317 | FLNB | P22T-E | Human | Esophagus | ESCC | 4.05e-09 | 2.26e-01 | 0.1236 |
| 2317 | FLNB | P23T-E | Human | Esophagus | ESCC | 7.29e-17 | 4.70e-01 | 0.108 |
| 2317 | FLNB | P24T-E | Human | Esophagus | ESCC | 5.35e-16 | 4.62e-01 | 0.1287 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00085445 | Breast | Precancer | epidermis development | 35/1080 | 324/18723 | 2.71e-04 | 3.96e-03 | 35 |
| GO:00099136 | Breast | Precancer | epidermal cell differentiation | 23/1080 | 202/18723 | 1.43e-03 | 1.50e-02 | 23 |
| GO:00302163 | Breast | Precancer | keratinocyte differentiation | 17/1080 | 139/18723 | 2.71e-03 | 2.39e-02 | 17 |
| GO:00605374 | Breast | Precancer | muscle tissue development | 37/1080 | 403/18723 | 3.60e-03 | 2.98e-02 | 37 |
| GO:00020649 | Breast | Precancer | epithelial cell development | 23/1080 | 220/18723 | 4.28e-03 | 3.35e-02 | 23 |
| GO:00147063 | Breast | Precancer | striated muscle tissue development | 35/1080 | 384/18723 | 5.10e-03 | 3.83e-02 | 35 |
| GO:006053711 | Breast | IDC | muscle tissue development | 50/1434 | 403/18723 | 4.91e-04 | 6.45e-03 | 50 |
| GO:000854412 | Breast | IDC | epidermis development | 41/1434 | 324/18723 | 1.03e-03 | 1.14e-02 | 41 |
| GO:000991312 | Breast | IDC | epidermal cell differentiation | 28/1434 | 202/18723 | 1.62e-03 | 1.60e-02 | 28 |
| GO:00147061 | Breast | IDC | striated muscle tissue development | 46/1434 | 384/18723 | 1.67e-03 | 1.63e-02 | 46 |
| GO:00302161 | Breast | IDC | keratinocyte differentiation | 21/1434 | 139/18723 | 2.06e-03 | 1.95e-02 | 21 |
| GO:00343414 | Breast | IDC | response to interferon-gamma | 21/1434 | 141/18723 | 2.46e-03 | 2.22e-02 | 21 |
| GO:00435883 | Breast | IDC | skin development | 33/1434 | 263/18723 | 3.46e-03 | 2.87e-02 | 33 |
| GO:000206414 | Breast | IDC | epithelial cell development | 28/1434 | 220/18723 | 5.53e-03 | 4.05e-02 | 28 |
| GO:00075172 | Breast | IDC | muscle organ development | 38/1434 | 327/18723 | 6.63e-03 | 4.62e-02 | 38 |
| GO:006053721 | Breast | DCIS | muscle tissue development | 50/1390 | 403/18723 | 2.39e-04 | 3.74e-03 | 50 |
| GO:00147062 | Breast | DCIS | striated muscle tissue development | 46/1390 | 384/18723 | 8.88e-04 | 1.01e-02 | 46 |
| GO:000854422 | Breast | DCIS | epidermis development | 40/1390 | 324/18723 | 1.05e-03 | 1.16e-02 | 40 |
| GO:000991322 | Breast | DCIS | epidermal cell differentiation | 27/1390 | 202/18723 | 2.11e-03 | 1.97e-02 | 27 |
| GO:00302162 | Breast | DCIS | keratinocyte differentiation | 20/1390 | 139/18723 | 3.24e-03 | 2.74e-02 | 20 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0513218 | Breast | Precancer | Salmonella infection | 49/684 | 249/8465 | 2.92e-09 | 6.15e-08 | 4.71e-08 | 49 |
| hsa0520514 | Breast | Precancer | Proteoglycans in cancer | 30/684 | 205/8465 | 1.00e-03 | 7.18e-03 | 5.50e-03 | 30 |
| hsa0513219 | Breast | Precancer | Salmonella infection | 49/684 | 249/8465 | 2.92e-09 | 6.15e-08 | 4.71e-08 | 49 |
| hsa0520515 | Breast | Precancer | Proteoglycans in cancer | 30/684 | 205/8465 | 1.00e-03 | 7.18e-03 | 5.50e-03 | 30 |
| hsa0513224 | Breast | IDC | Salmonella infection | 55/867 | 249/8465 | 2.07e-08 | 4.49e-07 | 3.36e-07 | 55 |
| hsa0520523 | Breast | IDC | Proteoglycans in cancer | 42/867 | 205/8465 | 7.69e-06 | 9.99e-05 | 7.48e-05 | 42 |
| hsa045109 | Breast | IDC | Focal adhesion | 32/867 | 203/8465 | 8.60e-03 | 4.23e-02 | 3.17e-02 | 32 |
| hsa0513234 | Breast | IDC | Salmonella infection | 55/867 | 249/8465 | 2.07e-08 | 4.49e-07 | 3.36e-07 | 55 |
| hsa0520533 | Breast | IDC | Proteoglycans in cancer | 42/867 | 205/8465 | 7.69e-06 | 9.99e-05 | 7.48e-05 | 42 |
| hsa0451013 | Breast | IDC | Focal adhesion | 32/867 | 203/8465 | 8.60e-03 | 4.23e-02 | 3.17e-02 | 32 |
| hsa0513243 | Breast | DCIS | Salmonella infection | 55/846 | 249/8465 | 8.71e-09 | 1.87e-07 | 1.38e-07 | 55 |
| hsa0520542 | Breast | DCIS | Proteoglycans in cancer | 39/846 | 205/8465 | 5.36e-05 | 5.58e-04 | 4.11e-04 | 39 |
| hsa0513253 | Breast | DCIS | Salmonella infection | 55/846 | 249/8465 | 8.71e-09 | 1.87e-07 | 1.38e-07 | 55 |
| hsa0520552 | Breast | DCIS | Proteoglycans in cancer | 39/846 | 205/8465 | 5.36e-05 | 5.58e-04 | 4.11e-04 | 39 |
| hsa0513220 | Cervix | CC | Salmonella infection | 74/1267 | 249/8465 | 1.33e-09 | 2.54e-08 | 1.50e-08 | 74 |
| hsa0520516 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
| hsa0451010 | Cervix | CC | Focal adhesion | 59/1267 | 203/8465 | 1.53e-07 | 1.84e-06 | 1.09e-06 | 59 |
| hsa040109 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
| hsa05132110 | Cervix | CC | Salmonella infection | 74/1267 | 249/8465 | 1.33e-09 | 2.54e-08 | 1.50e-08 | 74 |
| hsa0520517 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
| Page: 1 2 3 4 5 6 7 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FLNB | SNV | Missense_Mutation | novel | c.1132G>A | p.Asp378Asn | p.D378N | O75369 | protein_coding | deleterious(0.03) | probably_damaging(0.924) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
| FLNB | SNV | Missense_Mutation | novel | c.1797N>T | p.Gln599His | p.Q599H | O75369 | protein_coding | deleterious(0.01) | possibly_damaging(0.726) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD |
| FLNB | SNV | Missense_Mutation | c.1202N>A | p.Thr401Asn | p.T401N | O75369 | protein_coding | deleterious(0.02) | benign(0.03) | TCGA-A7-A26J-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| FLNB | SNV | Missense_Mutation | rs144158201 | c.2035N>T | p.Pro679Ser | p.P679S | O75369 | protein_coding | tolerated(0.15) | benign(0.314) | TCGA-A8-A08F-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
| FLNB | SNV | Missense_Mutation | rs768998920 | c.163N>C | p.Glu55Gln | p.E55Q | O75369 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| FLNB | SNV | Missense_Mutation | c.2166G>C | p.Trp722Cys | p.W722C | O75369 | protein_coding | tolerated(0.1) | probably_damaging(0.997) | TCGA-AR-A0TS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| FLNB | SNV | Missense_Mutation | rs80356520 | c.4912C>G | p.Arg1638Gly | p.R1638G | O75369 | protein_coding | deleterious(0.02) | possibly_damaging(0.726) | TCGA-AR-A1AP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
| FLNB | SNV | Missense_Mutation | novel | c.6208N>T | p.Val2070Leu | p.V2070L | O75369 | protein_coding | deleterious(0.01) | possibly_damaging(0.626) | TCGA-AR-A24M-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | SD |
| FLNB | SNV | Missense_Mutation | novel | c.3056N>T | p.Thr1019Ile | p.T1019I | O75369 | protein_coding | deleterious(0.02) | possibly_damaging(0.673) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| FLNB | SNV | Missense_Mutation | rs142229998 | c.7462N>A | p.Gly2488Ser | p.G2488S | O75369 | protein_coding | deleterious(0.02) | probably_damaging(0.926) | TCGA-BH-A208-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |